Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators

US10245264B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Joie Garfunkle · Metuchen, US
• Olga Ornoski · Teaneck, US
• Dann Parker · Cranford, US
• Subharekha Raghavan · Teaneck, US
• Libo Xu · Bound Brook, US

Key dates

• Filing date: May 23, 2016
• Grant date: Apr 2, 2019
• Expiry date: May 23, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or pharmaceutically acceptable salt thereofs, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or pharmaceutically acceptable salts thereof.